Solaris Vaccines develops novel vaccine candidates to address emerging global health threats. The company utilizes the SolaVAX™ method, which employs riboflavin and UV light to inactivate pathogens like viruses, bacteria, and parasites. This approach aims to create vaccines that are faster to produce, safer, and require less complex storage than current methods.
Funding
$110K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vaccine development and manufacturing methods can be slow, technically complex, and may involve toxic chemicals. These methods can also result in vaccines with demanding storage requirements and limited protective capabilities, hindering rapid response to emerging global health threats.
Solution
Solaris Vaccines addresses these challenges with its SolaVAX™ method, a novel approach to rapidly and effectively inactivate pathogens for vaccine creation. This method utilizes riboflavin (vitamin B2) and UV light to inactivate viruses, bacteria, and parasites. By streamlining the inactivation process, Solaris Vaccines aims to produce safer and more effective vaccines with less stringent storage requirements, enabling a quicker and more robust response to emerging infectious diseases.
Target Audience
The primary target audience includes global health organizations, government agencies, and pharmaceutical companies seeking rapid and effective vaccine solutions for emerging infectious diseases.
Features
- Rapid pathogen inactivation using riboflavin (vitamin B2) and UV light
- Versatile platform applicable to viruses, bacteria, and parasites
- Streamlined vaccine development and manufacturing process
- Aims to eliminate the need for toxic chemicals in vaccine production
- Designed to improve vaccine stability and reduce onerous storage requirements